BioMarin Pharmaceuticals, Inc. (BMRN)

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

COMPANY ADDRESS
105 Digital Drive
Novato, CA 94949
United States

COMPANY PHONE
415-506-6700

COMPANY WEBSITE



Get BioInvest's perspective on BioMarin's CEO


Latest Company News

BioMarin Pharmaceutical Inc. (BMRN) Given Average Rating of “Buy” by Analysts Chaffey Breeze - 5 hours ago BioMarin Pharmaceutical logo Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have earned a consensus recommendation of “Buy” from the twenty-two analysts that are covering the stock. What's Fueling Investor Confidence? – BioMarin Pharmaceutical Inc. (BMRN ... - USA Commerce Daily Verastem (NDAQ:VSTM) “Buy” Rating Maintained by HC Wainwright; The Target ... - Herald KS [...]
Fri, Mar 24, 2017 7:52:00 PM, Continue reading at the source
BioMarin Pharmaceutical (BMRN) Shares Cross Below 200 DMA Nasdaq - Mar 21, 2017 In trading on Tuesday, shares of BioMarin Pharmaceutical Inc. (Symbol: BMRN) crossed below their 200 day moving average of $89.05, changing hands as low as $88.51 per share. Buy or Sell? What Analysts Recommends: Univar Inc. (UNVR), BioMarin ... - StockNewsJournal BioMarin Pharmaceutical Inc. (BMRN) CEO Sells $916900.00 in Stock - The Cerbat Gem [...]
Tue, Mar 21, 2017 4:07:00 PM, Continue reading at the source
Insider Trading Activity BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – CFO Sold ... Market Exclusive - Mar 19, 2017 Daniel K Spiegelman , CFO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reportedly Sold 1,989 shares of the company's stock at an average price of 91.96 for a total transaction amount of $182,908.44 SEC Form. The BioMarin Pharmaceutical Inc. (BMRN) EVP Sells $205806.48 in Stock - Petro Global News 24 [...]
Sun, Mar 19, 2017 9:20:00 AM, Continue reading at the source
BioMarin Pharmaceutical Inc. Logs a Combined Blockbuster Motley Fool - Feb 25, 2017 BioMarin Pharmaceutical (NASDAQ:BMRN) logged over $1 billion in revenue -- the traditional level for a blockbuster -- for the first time in 2016. Instinet Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral - StreetInsider.com Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey - Benzinga [...]
Sat, Feb 25, 2017 4:41:00 PM, Continue reading at the source
Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Meanwhile, plenty of clinical-stage programs at Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) have been chugging along without much drama, but the stock is looking mighty expensive lately. [...]
Mon, Feb 20, 2017 1:41:00 PM, Continue reading at the source
BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 PR Newswire (press release) - Feb 15, 2017 SAN RAFAEL, Calif., Feb. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13th Annual WORLDSymposium™ being held ... [...]
Wed, Feb 15, 2017 1:35:00 PM, Continue reading at the source
Morgan Stanley Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight StreetInsider.com - Feb 7, 2017 Morgan Stanley initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating and a price target of $110.00. BioMarin to Host Fourth Quarter and Full Year 2016 Financial Results ... - PR Newswire (press release) BioMarin sues to stop generic version of its $90Ka-year drug - San Francisco Business Times [...]
Tue, Feb 07, 2017 8:48:00 AM, Continue reading at the source
BioMarin Pharmaceutical Inc.: Sales Up, Losses Down, Waiting on Pipeline Motley Fool - Oct 31, 2016 Revenue from Kuvan, up 42% year over year, continues to benefit from BioMarin's reacquisition of rights to overseas sales from its former partner Merck Serono. BioMarin Pharmaceutical (BMRN) Q3 2016 Results - Earnings Call Transcript - Seeking Alpha BioMarin's Product-Specific Performance in 3Q16 - Market Realist [...]
Mon, Oct 31, 2016 6:56:00 PM, Continue reading at the source
Solid BioMarin Pharmaceutical Inc. Earnings, More to Come Motley Fool - Aug 10, 2016 BioMarin Pharmaceuticals (NASDAQ:BMRN) reported second-quarter earnings last week. While the biotech's current drugs are still growing at a nice pace, it's BioMarin's pipeline, including two drugs that have already read out positive phase 3 data, that ... BioMarin Pharma's (BMRN) 7.5M Common Stock Offering Prices at $96/Share - StreetInsider.com Investors Snatch BMRN 5.6% Cheaper Than Its Secondary Stock Offering - Forbes [...]
Wed, Aug 10, 2016 8:00:00 PM, Continue reading at the source
Why BioMarin Pharmaceutical Inc. Stock Rose 22.2% in July Motley Fool - Aug 6, 2016 What: Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biopharmaceutical company focused on diseases with unmet need, gained 22.2% in July, according to data from S&P Global Market Intelligence. BioMarin: The Tesla Of Biotech - Seeking Alpha [...]
Sat, Aug 06, 2016 4:43:00 PM, Continue reading at the source